• The company will host a stakeholder update call on August 13, 2026, to discuss second-quarter financial results and business initiatives.
• Beeline is using artificial intelligence and automation to shorten mortgage approval and closing timelines while serving both homebuyers and real estate investors.
• Beeline is addressing financing challenges facing Millennials and Generation Z through digital underwriting designed to provide rapid qualification assessments.
• The company is also expanding products aimed at older homeowners seeking to access home equity without refinancing existing low-rate mortgages.
• Q1 2026 results showed revenue and loan originations more than doubling from the prior-year period despite a challenging mortgage market.
• Beeline’s strategy combines mortgage origination, title services and software solutions to create multiple revenue opportunities within residential real estate finance.

Beeline Holdings (NASDAQ: BLNE), a fast-growing digital mortgage platform offering a quicker and easier path to homeownership, is preparing to provide investors with its latest operating update as the mortgage technology company continues expanding its digital lending platform during a period of ongoing change in the U.S. housing market.

The company announced it will host a stakeholder update call on August 13, 2026, following the release of its second-quarter financial results. Chief Executive Officer Nick Liuzza and Chief Financial Officer Chris Moe are expected to review quarterly performance and discuss the company’s strategic initiatives. (https://ibn.fm/pYl3T).

The upcoming call arrives as mortgage lenders continue adapting to elevated interest rates, affordability constraints and changing borrower demographics that have reshaped residential real estate finance over the past several years. Rather than relying solely on traditional mortgage origination, Beeline has positioned itself as a technology-focused platform that uses artificial intelligence, automation and digital workflows to streamline the lending process.

Headquartered in Providence, Rhode Island, the company operates primarily through its wholly owned subsidiary, Beeline Loans Inc., offering conventional mortgages alongside non-qualified mortgage (Non-QM) products designed for borrowers whose financial profiles may not fit traditional underwriting models. 

Beeline’s strategy centers on reducing friction throughout the mortgage process. The company’s proprietary technology platform incorporates its AI-powered virtual assistant, Bob, together with its production engine known as Hive, allowing borrowers to complete much of the mortgage process digitally. According to the company, loans can close in approximately 14 to 21 days, significantly below traditional industry timelines.

Artificial intelligence also plays an expanding role in the underwriting process. Management says the platform can provide prospective borrowers with an initial qualification assessment in roughly seven to eight minutes while delivering approximately 90% certainty regarding mortgage eligibility. The objective is to give applicants earlier clarity while reducing delays typically associated with manual underwriting.

The company’s technology strategy is particularly relevant for younger borrowers facing persistent barriers to homeownership. According to reporting by National Mortgage Professional, homeownership rates remain relatively low among younger generations, with only 26.1% of Generation Z consumers and 54.9% of Millennials owning homes during 2024. Limited access to mortgage financing continues to be one of the principal challenges confronting first-time buyers.

Beeline is attempting to address that gap by serving not only traditional owner-occupied purchases but also younger consumers seeking to purchase residential investment properties. Management believes many Millennials and Gen Z borrowers increasingly view income-producing real estate as an alternative pathway toward long-term wealth creation, particularly as affordability challenges continue affecting primary housing markets.

This emphasis on investment-property financing distinguishes part of Beeline’s business model from lenders focused primarily on owner-occupied mortgages. The company has continued expanding its portfolio of debt-service coverage ratio loans and bank-statement lending products, which are frequently used by self-employed borrowers and residential property investors who may not qualify under conventional income documentation requirements.

Recent financial results suggest the strategy is gaining traction. During the first quarter of 2026, Beeline reported revenue of $2.7 million, more than doubling from the same period a year earlier. Loan originations increased to $85.6 million across 288 loans, compared with $39.8 million and 128 loans during the prior-year quarter.

Rather than pursuing origination volume alone, management has indicated that profitability and operational efficiency remain priorities while interest rates and housing activity continue to fluctuate. During the company’s first-quarter earnings discussion, executives emphasized expanding lending categories that offer stronger economics while continuing to automate internal processes.

Operational data released by the company also points to improving customer engagement. Management reports that Bob has increased lead-to-lock conversion rates by approximately 8% among online borrowers, while Beeline’s self-service mortgage workflow generated a 131% improvement in application-to-lock pull-through during early deployment.

At the same time, Beeline is broadening its addressable market beyond younger homebuyers. Through BeelineEquity, the company is targeting homeowners who accumulated substantial home equity during years of rising residential property values but are reluctant to refinance mortgages originated during the historically low interest-rate environment of 2020 and 2021.

Management estimates that older homeowners collectively hold approximately $10 trillion in housing equity. BeelineEquity is designed to help homeowners access a portion of that equity without replacing their existing mortgages. Because the platform primarily generates fee income rather than holding loans on its balance sheet, the business provides an additional revenue stream that differs from traditional mortgage lending.

The company is also investing in complementary software capabilities that extend beyond mortgage origination. Beeline maintains a minority interest in MagicBlocks, an artificial intelligence platform supporting sales automation that management says has begun attracting adoption among larger financial institutions.

Beeline is balancing growth with operational discipline while expanding across multiple segments of residential real estate finance. As housing affordability, demographic shifts and digital adoption continue reshaping the mortgage industry, the company’s strategy reflects a broader trend toward technology-enabled lending platforms designed to serve a wider range of borrowers, including younger consumers entering both homeownership and property investing, as well as long-time homeowners seeking new ways to access accumulated housing equity.

For more information, visit the company’s website at www.MakeABeeline.com.

NOTE TO INVESTORS: The latest news and updates relating to BLNE are available in the company’s newsroom at https://ibn.fm/BLNE

• We believe that the decision between debt and equity is one of the most consequential a business owner will ever make, and it is rarely as simple as comparing interest rates to dilution percentages.
• The challenge is that middle-market businesses do not always have clean access to traditional bank financing.
• That diagnostic work is precisely where Market Street Capital’s capital markets practice seeks to add value.

When a founder needs capital to grow, two doors open simultaneously; choosing the wrong one can reshape the company’s future in ways that take years to fully understand. A boutique capital markets and financial advisory firm, Market Street Capital’s team members have spent more than two decades helping established middle-market business owners think clearly about exactly that choice. The company works at the intersection of strategic advisory and sophisticated capital raising, helping founders navigate the debt-versus-equity decision with the kind of institutional expertise that has historically been reserved for much larger companies.

The decision between debt and equity is one of the most consequential a business owner will ever make, and it is rarely as simple as comparing interest rates to dilution percentages. Both paths carry long-term implications for ownership, control, cash flow and strategic flexibility. Getting it right requires understanding not just the mechanics of each instrument, but the moment the business is in, the trajectory it is on and what the capital is intended to accomplish.

At its core, the tradeoff is straightforward. Debt preserves ownership and avoids dilution but creates fixed repayment obligations regardless of business performance. Interest payments are typically tax deductible, which reduces the true cost of borrowing, though founders should consult their own tax advisors, but covenant packages and collateral requirements can constrain operational flexibility.

Equity, by contrast, carries no repayment burden and aligns investors’ returns with the company’s success. However, it permanently reduces the founder’s share of future profits and can introduce new governance dynamics, including board seats and investor influence over major decisions.

According to Carta’s 2025 year-end State of Private Markets report, median dilution across all rounds from seed through Series C fell from approximately 18% to 16% last year, continuing a multiyear downward trend. That said, founders raising equity at any stage should still expect to give up a meaningful share of ownership per round, and those figures reflect a market where investor selectivity has increased alongside deal sizes.

For middle-market founders running established, cash-generating businesses, debt is frequently the more efficient tool. According to PitchBook’s NVCA Venture Monitor, U.S. venture debt volume reached $58.7 billion in 2024, double the volume from 2023, reflecting strong founder demand for growth capital that does not require giving up ownership. Established companies with predictable revenue streams are well positioned to service debt, and doing so allows them to fund acquisitions, expansion or recapitalizations without reducing their share of the upside. According to Phoenix Strategy Group, the after-tax cost of debt financing typically runs between 3 and 8%, while equity investors generally expect returns of 15 to 25%, making debt significantly less expensive for founders who have the cash flow to support it.

The challenge is that middle-market businesses do not always have clean access to traditional bank financing. Post-2008 regulatory requirements pushed banks toward tighter lending standards, particularly for companies without investment-grade credit ratings or substantial hard assets. That structural gap created the conditions for a private credit market that has grown dramatically in response.

According to Morgan Stanley, the private credit market stood at approximately $2 trillion in 2020, grew to $3 trillion entering 2025, and is projected to reach approximately $5 trillion by 2029. Much of that growth is driven by middle-market borrowers who cannot access broadly syndicated loan markets but need flexible, sophisticated financing solutions. For founders in this segment, the universe of debt options has expanded substantially and can include senior debt, unitranche facilities, mezzanine financing, asset-based lending and specialty structures. Each option offers different risk profiles, covenant packages and pricing dynamics.

Mezzanine financing and unitranche structures occupy particularly important roles in middle-market finance, offering borrowers alternatives to traditional bank lending. Mezzanine debt sits between senior debt and equity in the capital stack, providing subordinated capital that fills the gap between what a senior lender will provide and the equity a borrower wants to contribute. Unitranche financing combines senior and subordinated debt into a single credit facility governed by one loan agreement and one blended interest rate, simplifying the borrowing process and often accelerating deal timelines compared to traditional multi-tranche structures.

Both instruments generally provide greater flexibility than conventional bank loans and can reduce the need for an immediate equity raise. These financing solutions are especially common in acquisitions, recapitalizations and growth initiatives where a company requires more capital than traditional senior lenders are willing to provide but seeks to minimize equity dilution.

Equity, however, remains the right answer in specific circumstances. In corporate finance, debt is often best suited for investments with relatively predictable cash flows and identifiable returns, while equity can be a better fit for strategic initiatives that carry greater uncertainty but offer transformational upside. For founders pursuing a genuinely transformational initiative, such as entering a new market, making a significant platform acquisition or funding a new product line that may not generate returns for several years, patient equity capital from aligned investors can provide greater financial flexibility than debt, which requires scheduled principal and interest payments regardless of business performance. Ultimately, the question is not which financing instrument is inherently superior but which one best aligns with a company’s objectives, cash flow profile, and long-term strategy.

That diagnostic work is precisely where Market Street Capital’s capital markets practice adds value. The firm’s Debt Capital Markets and Specialty Lending practice is built specifically for the middle market, connecting clients with senior debt facilities, unitranche and mezzanine structures, asset-based lending and tailored specialty financing through relationships with banks, private credit funds, insurance companies and specialty finance providers.

For founders who determine that equity is the right path, Market Street’s Private Equity Raises practice structures and executes customized raises with access to institutional investors, family offices and private equity sponsors across a large investor network. The company describes its philosophy as ensuring that financing structures support sustainable growth and long-term enterprise value, not just the immediate transaction. For founders confronting the debt-versus-equity question, that kind of independent, structuring-focused advisory can help inform a capital decision that supports the company’s long-term flexibility and options.

Securities transactions offered through Pickwick Capital Partners, LLC, an SEC registered broker dealer member of FINRA and SIPC. Principals of Market Steet Capital are registered representatives of Pickwick.

This communication is for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any security, nor an offer to provide any investment, advisory, tax, or legal service. It is not investment, tax, or legal advice, and recipients should consult their own advisors. Market-data statistics are attributed to the third-party sources identified herein, which Market Street Capital believes to be reliable but has not independently verified and does not guarantee. Any statements regarding transaction processes or outcomes are illustrative; results depend on individual facts and market conditions and are not guaranteed, and past or current market conditions may not continue.

For more information, visit www.MarketStreetCP.com.

NOTE TO INVESTORS: The latest news and updates relating to Market Street are available in the company’s newsroom at https://ibn.fm/MarketSt

• The company is expanding its presence in the global surgical robotics market through its proprietary SSi Mantra robotic surgery platform.
• The company’s strategy combines world-class robotic systems, including telesurgery capabilities, with affordability, physician training, and international market expansion.
• More than 200 SSi Mantra systems have been installed worldwide, supporting over 12,000 robotic procedures across more than 170 surgical indications.
• SS Innovations continues pursuing U.S. FDA clearance and European regulatory approvals while building its installed base internationally.
• Growing demand for minimally invasive surgery and broader access to robotic procedures continues to create opportunities for emerging high-tech medical technology companies.

The market for robotic-assisted surgery continues to evolve as healthcare systems seek technologies that can improve surgical precision while expanding patient access. Within that landscape, SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has positioned itself around a strategy centered on unmatched technology, physician training, international expansion, and affordability. Serving as the foundation of its commercial efforts is the company’s proprietary SSi Mantra surgical robotic system.

Unlike many developers focused primarily on premium hospital systems, SS Innovations has concentrated on reducing the economic barriers that have limited adoption of robotic surgery in many regions. The company believes lowering acquisition and operating costs can allow more hospitals to introduce robotic-assisted procedures without sacrificing advanced functionality.

That strategy has translated into continued operational growth. According to the company, more than 200 SSi Mantra systems have now been installed globally, supporting more than 12,000 multi-specialty robotic procedures, including cardiac surgery, pediatric procedures and robotic telesurgery. The platform has also been used across more than 170 different surgical procedures, illustrating its applicability across multiple clinical specialties.

Cardiac surgery remains an area of particular differentiation. While several robotic platforms are designed primarily for soft-tissue procedures, SS Innovations has invested heavily in robotic cardiac surgery, one of the most technically demanding surgical disciplines. The company reports that the SSi Mantra has supported more than 650 cardiac procedures, providing surgeons with robotic capabilities for complex minimally invasive operations.

The platform incorporates three to five modular robotic arms, an open-console surgeon workstation, high-definition 3D visualization and a portfolio of more than 40 robotic surgical instruments. The company has also developed complementary SSi Mudra instruments that support a broad range of minimally invasive procedures.

Beyond the operating room, SS Innovations has devoted considerable resources to telesurgery. Although remote robotic surgery remains an emerging field and is not currently the company’s primary commercial business, it represents an area receiving increasing attention across healthcare. The SSi Mantra platform has now been used in more than 170 telesurgery procedures, including more than 20 cardiac telesurgeries, which the company says makes it the only robotic surgical platform to have performed cardiac telesurgery.

Management views telesurgery as part of a broader effort to extend specialist surgical expertise into communities where experienced robotic surgeons may not be physically available. Related teleproctoring technologies also allow experienced physicians to mentor surgeons remotely during procedures.

Equally important to the company’s long-term strategy is physician education. Earlier this month, SS Innovations graduated the inaugural class of its SS International Centre for Robotics Surgery (“SSICRS”) cardiac robotic surgery training program. The five-day course brought together 33 healthcare professionals from seven countries for classroom instruction, laboratory sessions, live surgical demonstrations and hands-on robotic training.

The company intends to expand the educational program beyond cardiac surgery into additional specialties including urology, gynecology, thoracic surgery, gastrointestinal procedures, colorectal surgery and general surgery.

Corporate leadership continues to evolve alongside commercial expansion. SS Innovations recently announced the appointment of veteran medical technology executive Sarah M. Romano as Chief Financial Officer, effective August 3. Romano brings more than two decades of public-company finance and capital markets experience, including leadership positions with emerging medical technology companies. According to the company, she has helped raise more than $100 million during her career.

Management believes the appointment strengthens financial leadership as SS Innovations expands internationally while continuing preparations for U.S. regulatory review.

Regulatory progress remains another important focus. The company continues pursuing U.S. Food and Drug Administration (“FDA”) clearance for the SSi Mantra platform while also advancing European certification activities. Entry into additional regulated markets could significantly expand the company’s commercial opportunities over time, although regulatory review remains an ongoing process.

Artificial intelligence also forms part of SS Innovations’ longer-term development roadmap. According to CEO and founder Dr. Sudhir Srivastava, AI already contributes to certain safety functions within the robotic platform, while future development may incorporate additional imaging capabilities, workflow automation and greater surgical assistance. The company is also evaluating specialty-specific robotic platforms, pediatric applications, mobile operating units and robotics designed for military and disaster-response environments.

The broader market backdrop continues to support interest in robotic surgery. Hospitals increasingly seek minimally invasive techniques that may shorten recovery times and improve procedural precision. The unmatched technology behind the SSi Mantra robotic surgery platform meets this need, while also offering affordability for healthcare providers balancing clinical benefits against capital costs.

For more information, visit the company’s website at www.SSInnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII

• Exit readiness is one of the most important and most overlooked strategic disciplines for founders of privately held businesses.
• One of the most common mistakes founders make is waiting until they are emotionally ready to sell before beginning any preparation.
• Market Street Capital’s advisory practice helps founders organize their records, align their team and prepare their narrative.

Most business owners spend years building something worth selling, then spend far too little time thinking about how to actually sell it. That gap between building a valuable company and knowing when and how to exit is where significant value is won or lost. Market Street Capital exists to close that gap.

Based in Houston, Market Street Capital is a boutique capital markets and financial advisory firm with more than 14 years of experience helping established middle-market businesses navigate pivotal moments in their development, including mergers and acquisitions (“M&A”), capital raises, restructurings, valuations and IPO readiness. The firm’s tagline — Where Main Street Meets Wall Street — reflects its founding principle: Founders and business owners deserve the same institutional-quality advisory that larger companies receive as a matter of course.

Exit readiness is one of the most important and most overlooked strategic disciplines for founders of privately held businesses. Many owners assume they will know when the time is right to sell. The reality is more complicated. Timing a business sale involves reading the market, understanding what buyers are paying, knowing what a business looks like from the outside and being operationally prepared for the scrutiny that follows. Each of those elements requires advance work, and most of that work needs to happen long before a founder ever speaks to a potential buyer.

The current market environment makes this conversation more relevant than ever. According to Capstone Partners’ Middle Market M&A Valuations Index, average M&A valuations for middle-market businesses settled at 9.8x EV/EBITDA in 2025, up from 9.4x in 2024 and 9.0x in 2023. That trend reflects resilience in quality assets even against a backdrop of macroeconomic uncertainty. Middle market M&A volume rose 10.7% year-over-year in Q1 2026, and total exit value surged 57.1% in 2025 to $589.2 billion, reflecting a concentration of larger, high-quality deals clearing the market. For well-prepared founders, current conditions can be constructive; however, market conditions vary and may change, and capitalizing on them requires preparation, not just intention.

One of the most common mistakes founders make is waiting until they are emotionally ready to sell before beginning any preparation. A well-run sell-side M&A process typically takes nine to twelve months from kickoff through close, with faster timelines possible when financials are clean and diligence is straightforward. That means the decision to sell needs to precede the sale itself by a full year or more. Owners who wait until they are burned out, or until a buyer approaches them unsolicited, typically negotiate from a weaker position and leave value behind.

Exit readiness preparation means building the kind of company that buyers want to buy, not just the kind that operates well. Buyers examine three to five years of audited financials, customer concentration, recurring revenue quality, employee key-person dependencies, and legal and compliance records. The findings that most frequently move price or kill deals include customer concentration above 40% of revenue, working capital shortfalls, undisclosed litigation, and key-person dependencies. A founder who has addressed those issues before coming to market is far better positioned than one who discovers them in the middle of a due diligence process.

These figures are averages, however, and the range for any individual business is shaped by profitability, growth rate, customer quality, management depth and operational consistency. Understanding where a business falls within that range, and what it would take to move it toward the upper end, is fundamental strategic work that is best done well before a sale process begins.

The due diligence process itself is another area where founders are frequently unprepared. For a middle-market deal between $50 million and $500 million, due diligence typically runs six to twelve weeks and covers financial records, legal matters, operations, customer relationships, employee agreements, technology systems and environmental considerations. Running a business while simultaneously responding to a buyer’s due diligence requests is genuinely difficult, and the founders who navigate it best are those who have organized their records, aligned their team and prepared their narrative before the process begins.

This is exactly where Market Street Capital’s advisory practice adds meaningful value. The firm’s Strategic Planning and Advisory offering is built to guide founders and shareholders through the full strategic decision cycle, from evaluating whether and when to sell, to structuring the right kind of process, to managing the transaction through close.

The firm’s Mergers and Acquisitions practice covers the full spectrum of sell-side advisory, helping founders craft compelling narratives, manage competitive buyer processes and negotiate terms intended to manage downside risk and pursue value. With access to a syndication network of more than 8,000 investors, family offices, venture capital firms and banks, Market Street brings the buyer relationships that determine whether a sale process generates genuine competition or a single take-it-or-leave-it offer.

Founders who have built something substantial deserve both a process that reflects that value and an advisor who understands what the business is worth and what the right exit actually looks like. That is the work Market Street Capital was built to do.

Securities transactions offered through Pickwick Capital Partners, LLC, an SEC registered broker dealer member of FINRA and SIPC. Principals of Market Steet Capital are registered representatives of Pickwick.

This communication is for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any security, nor an offer to provide any investment, advisory, tax, or legal service. It is not investment, tax, or legal advice, and recipients should consult their own advisors. Market-data statistics are attributed to the third-party sources identified herein, which Market Street Capital believes to be reliable but has not independently verified and does not guarantee. Any statements regarding transaction processes or outcomes are illustrative; results depend on individual facts and market conditions and are not guaranteed, and past or current market conditions may not continue.

For more information, visit www.MarketStreetCP.com.

NOTE TO INVESTORS: The latest news and updates relating to Market Street are available in the company’s newsroom at https://ibn.fm/MarketSt

• Regulatory clarity: ATF Ruling 2026-2, effective July 2, 2026, classified the BolaWrap(R) 150 as a federally recognized instrument of restraint rather than a firearm or “any other weapon” — which may remove longstanding procurement barriers across law enforcement, corrections, and government markets and is helping agencies move from extended evaluation toward department-wide programs.
• Counter-drone sensing: A strategic transaction with Israeli AI sensing company Frenel Imaging Ltd. gives WRAP exclusive U.S. and NATO distribution rights to Division of Focal Plane (“DoFP”) polarimetric sensing technology, which detects drones by their physical light-scattering signatures rather than radio-frequency emissions — enabling detection, the company says, even after a drone stops transmitting. WRAP describes it as the detection layer of its emerging WrapShield(TM) platform.
• A three-part response layer: With the first operational Wraptor MX(TM) prototype and an early-adopter program, WRAP is positioning a three-component Non-Lethal Response(TM) architecture — BolaWrap(R) 150 (handheld restraint), Wraptor MX(TM) (multi-shot platform), and the developing DFR-X(TM) (drone-deployed restraint) — around a common operating framework.

For the agencies adopting them, non-lethal tools share a single measure of success: a tense encounter that ends with everyone going home safely — the person in crisis, the officer responding, and the community watching. That standard sits at the center of Wrap Technologies (NASDAQ: WRAP) pitch to public safety buyers, and the company is now expanding the range of situations its platform is built to address.

Wrap Technologies entered the third quarter of 2026 reporting continued adoption of its Non-Lethal Response(TM) system across public safety agencies, alongside approximately $1.2 million in international orders and a reaffirmed target of roughly 100% year-over-year revenue growth in 2026, according to the company. WRAP also announced a strategic transaction with Israeli AI sensing company Frenel Imaging Ltd., acquiring exclusive U.S. and NATO distribution rights to physics-based polarimetric sensing technology that it says will underpin its emerging WrapShield(TM) counter-unmanned aircraft system (“UAS”) platform.

Taken together with the recent unveiling of the company’s Wraptor MX(TM) multi-shot restraint platform, the announcements point to both near-term commercial traction and a longer-term shift in how WRAP positions itself: less as a maker of a single device and more as a provider of an integrated system spanning restraint instruments, operational doctrine, sensing technology, and command-and-control — a platform the company says addresses several public safety and security markets at once.

The newly reported orders span two markets. In Brazil, distributors placed orders supporting deployments with multiple public safety agencies, while an additional order in India strengthens the company’s presence in one of the world’s largest public safety markets. WRAP says much of the activity reflects repeat customer demand, which it characterizes as a sign that agencies are moving beyond initial evaluation toward broader operational use. The company reports its Non-Lethal Response(TM) system has been validated by more than 1,000 agencies across 60+ countries, with headquarters in Miami, Florida and manufacturing in Norton, Virginia.

“We are entering the third quarter with meaningful commercial momentum already in place,” said Scot Cohen, Chief Executive Officer of WRAP (ibn.fm/v4TtD). “Opening the quarter with significant international orders is encouraging on its own, but what matters more is what those orders represent — repeat customers expanding their deployments and new markets adopting our technology.”

The company also pointed to ATF Ruling 2026-2, effective July 2, 2026, issued by the U.S. Bureau of Alcohol, Tobacco, Firearms and Explosives (“ATF”), which classified the BolaWrap(R) 150 as an instrument of restraint rather than a firearm or “any other weapon.” WRAP’s management believes the decision clarifies a longstanding regulatory question that had complicated procurement in certain markets and expects it to support both domestic and international interest, though the commercial impact will play out over time. According to the company, some agencies that had kept the BolaWrap(R) 150 under extended evaluation are now moving to formal, department-wide Non-Lethal Response(TM) programs — pairing the instrument with WrapTactics(R) operational doctrine training. Management characterizes that shift, from device evaluation to institutional commitment, as its most significant domestic adoption signal since commercial launch, though independent confirmation of the pace of that conversion is not yet available.

While the BolaWrap(R) 150 remains the anchor of its commercial business, WRAP is broadening the WrapShield(TM) platform. Alongside the counter-drone sensing initiative, the company recently introduced the first operational prototype of WraptorMX(TM), a modular multi-shot restraint platform aimed at tactical teams, corrections, and perimeter security. According to WRAP, the prototype extends the platform’s non-lethal response layer beyond the handheld BolaWrap(R) 150 and complements a developing drone-deployed restraint system, DFR-X(TM), forming a family of proportionate response options built around a common operating architecture.

Through the Frenel Imaging transaction, WRAP acquired exclusive U.S. and NATO distribution rights to proprietary Division of Focal Plane (“DoFP”) polarimetric sensing technology, which the company says detects objects by their physical light-scattering signatures rather than their electronic emissions — enabling detection even after a drone stops transmitting. WRAP describes the technology as the detection layer of WrapShield(TM), an integrated platform intended to combine threat detection, AI-assisted decision support, and multiple non-lethal response options under a single operating architecture.

The move targets a growing problem for governments and security agencies. Consumer drones have become common tools for smuggling contraband into correctional facilities, conducting unauthorized surveillance, supporting cross-border criminal activity, and disrupting military installations and critical infrastructure. Traditional counter-drone systems often rely on radar or radio-frequency detection, which can leave gaps when drones operate autonomously or cease transmitting — a limitation the company argues its newly licensed sensing technology helps address. Independent validation of that capability in the field is not yet publicly available.

Collectively, the steps mark a measured evolution from a single-product provider toward an integrated public safety platform. The BolaWrap(R) 150 remains the commercial foundation; Wraptor MX(TM) broadens response options for multi-engagement scenarios; and DFR-X(TM) would extend those capabilities to drone-based deployment. Combined with WrapShield(TM)’s AI-enabled sensing and command architecture, WRAP is assembling a layered system meant to help agencies detect, assess, and respond to evolving threats using proportionate, non-lethal options.

As governments continue investing in officer safety and modern public safety technology, WRAP is positioning across several complementary markets rather than relying on a single product. Whether that breadth translates into sustained growth will depend on execution, the pace of agency adoption, and how quickly the newer platforms move from prototype to deployment. As Cohen put it, management believes the developments reinforce its conviction that WRAP is building “a differentiated public safety technology platform positioned for long-term growth.”

For more information, visit the company’s website at wrap.com.

NOTE TO INVESTORS: The latest news and updates relating to WRAP are available in the company’s newsroom at https://ibn.fm/WRAP

About / Disclaimer

This article was produced by IBN Editorial Staff and is intended for informational purposes only. It is not investment advice and should not be relied upon as the basis for any investment decision. Statements attributed to Wrap Technologies Inc. or its management, including any forward-looking statements regarding revenue growth, product development, or market opportunities, reflect the company’s views and are subject to risks and uncertainties; actual results may differ materially. Readers should conduct their own due diligence and consult a qualified professional. Additional company information is available at wrap.com.

• The company has appointed antibody therapeutics specialist Dr. Christoph Erkel as Chief Scientific Officer.
• The leadership change comes as the company advances its proprietary BiTAC(R) technology platform toward clinical development.
• VERAXA is building a diversified oncology pipeline that includes conditionally active T-cell engagers, bispecific ADCs and other engineered antibody therapeutics.
• Recent regulatory feedback from Germany’s Paul-Ehrlich-Institute has provided additional clarity for development of the company’s lead BiTAC(R)-TCE program.
• Investors are watching companies developing next-generation immunotherapies that seek to improve efficacy while reducing treatment-related toxicity.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has appointed antibody therapeutics researcher Christoph Erkel, Ph.D., as Chief Scientific Officer, reinforcing the company’s focus on advancing its proprietary BiTAC(R) technology platform as it prepares its lead oncology programs for clinical development. The announcement comes at a time when the biotechnology company is moving several elements of its research pipeline forward while expanding its scientific and regulatory capabilities.

According to the company, Dr. Erkel previously served as Vice President of Research & Development, where he helped oversee development of VERAXA’s antibody therapeutics portfolio. In his new role, he will lead scientific strategy across the company’s BiTAC(R) platforms and broader oncology pipeline while directing efforts to accelerate product candidates toward human clinical trials (https://ibn.fm/fc9tP).

Dr. Erkel brings approximately two decades of experience in antibody engineering, immuno-oncology research and preclinical drug development. Before joining VERAXA, he led therapeutic research programs at MorphoSys AG, where he worked on conditionally active T-cell engagers and other antibody-based therapies prior to the company’s acquisition by Novartis. His career has also included leadership positions in antibody engineering and molecular biology, spanning both scientific discovery and candidate development.

The appointment reflects a broader phase of development for VERAXA as it seeks to translate laboratory research into clinical-stage oncology programs. The company’s strategy centers on antibody therapeutics designed to improve the precision of cancer treatment. While traditional immunotherapies have transformed oncology, researchers continue searching for approaches that preserve anti-tumor activity while minimizing damage to healthy tissue.

VERAXA’s lead development program is built around its proprietary BiTAC(R)-TCE technology, a conditionally active bispecific T-cell engager designed to recognize two tumor-associated markers before activating an immune response. Management believes this dual-targeting approach may improve selectivity by directing immune cells primarily toward cancer cells expressing both markers, potentially reducing activity against healthy cells displaying only one target.

Earlier this month, the company also announced encouraging regulatory progress after receiving Scientific Advice from Germany’s Paul-Ehrlich-Institute, which supported the biological rationale and proposed non-clinical development strategy for its lead BiTAC(R)-TCE candidate. The feedback provided additional clarity as the program advances toward future regulatory submissions.

Initial preclinical findings presented at the American Association for Cancer Research (“AACR”) Annual Meeting in April demonstrated that the company’s lead candidate selectively attacked cancer cells expressing both target molecules while sparing cells expressing only one marker. According to VERAXA, those studies also indicated efficacy comparable to conventional T-cell engagers while suggesting the potential for an improved therapeutic index if confirmed in future development.

Questions Investors May Be Asking About BiTAC(R)

What makes BiTAC(R) different from conventional T-cell engagers?

Traditional T-cell engagers generally activate immune cells whenever a single target is detected, which can increase the risk of attacking healthy tissues that also express that marker. VERAXA’s BiTAC(R) technology is designed to require recognition of two tumor-associated targets before triggering immune-cell activation, an approach intended to increase selectivity and potentially improve safety. A conditionally active T-cell binding CD3 domain adds another layer of safety control to BiTAC-TCEs.

Why is there continued demand for new T-cell engager technologies?

Although T-cell engagers have become an important area of cancer drug development, many researchers continue working to reduce treatment-related toxicity while expanding their use against solid tumors. Technologies that improve targeting precision could broaden the range of patients who may benefit from these therapies if clinical results support the approach.

Where do antibody-drug conjugates (“ADCs”) fit into VERAXA’s strategy?

Beyond BiTAC(R), VERAXA is developing a broader pipeline that includes other bispecific antibody-drug conjugate formats. ADCs combine antibodies with potent therapeutic payloads that are delivered directly to cancer cells, while bispecific formats seek to further improve targeting by recognizing multiple biomarkers simultaneously. Together, these platforms provide multiple development opportunities across different cancer indications.

VERAXA’s broader strategy extends beyond a single product candidate. The company is building a diversified oncology pipeline that includes conditionally active T-cell engagers, bispecific antibody-drug conjugates and additional engineered antibody formats designed for solid tumors and other cancer types.

For more information, visit the company’s website at www.Veraxa.com.

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA

• The company has appointed Alec Rossa as Chief Revenue Officer to lead commercialization, strategic partnerships, and deployment of the company’s planned Power-as-a-Service (“PaaS”) business model.
• Management says early commercial opportunities include AI data centers, industrial facilities, defense applications and other energy-intensive infrastructure.
• The company is pursuing a strategy that combines technology development, intellectual property protection and recurring revenue through long-term Power-as-a-Service agreements.
• American Fusion(TM) recently highlighted progress on its Texas Tech University testing program, following regulatory authorization covering all twelve Texatron(TM) Fusion Engine(TM) research systems.
• American Fusion(TM) has also expanded its intellectual property portfolio to 76 U.S. patent applications, moving toward its long-term objective of filing more than 260 patent applications.

American Fusion(TM) (OTC: AMFN), a developer of next-generation fusion energy technologies, has strengthened its commercial leadership with the appointment of Alec Rossa as Chief Revenue Officer, a move that reflects the company’s increasing focus on preparing its fusion technology platform for future commercialization alongside ongoing engineering and testing activities.

The announcement, made on July 22, assigns Rossa responsibility for leading American Fusion’s(TM) global commercial strategy, including customer development, government and institutional relationships, strategic partnerships and deployment planning for the company’s proposed Power-as-a-Service (“PaaS”) model (https://ibn.fm/vyobC).

Rossa brings nearly two decades of executive leadership experience from MD Charlton Ltd., where he served as President and Chief Executive Officer of one of Canada’s largest distributors of police and tactical equipment. During that period, he developed relationships with military organizations, law enforcement agencies, emergency response organizations and government procurement departments while overseeing complex commercial agreements and institutional sales programs.

For American Fusion(TM), those relationships align with management’s view that future demand for advanced power generation could extend beyond commercial utilities into government, defense and critical infrastructure markets.

The company’s long-term business strategy differs from a traditional equipment sales model. Rather than simply manufacturing reactors for customers, American Fusion(TM) intends to own, operate and maintain Texatron(TM) Fusion Engine(TM) systems while selling electricity through long-term Power-as-a-Service agreements. Management believes that approach could allow customers to access reliable baseload power without making large upfront capital investments while creating recurring revenue opportunities for the company over the operational life of installed systems.

The commercial appointment comes as American Fusion(TM) continues advancing the engineering program supporting its proprietary fusion platform.

In a recent interview summarized by the company, Executive Chairman Brent Nelson outlined several operational milestones, including progress following receipt of certification from the Texas Department of State Health Services (“DSHS”) that authorizes research involving all twelve registered Texatron(TM) Fusion Engine(TM) models at Texas Tech University (https://ibn.fm/g8G2D).

According to Nelson, the certification allows the company to proceed with the next phase of testing after months of regulatory preparation. Testing activities at Texas Tech University are expected to focus initially on validating fusion reactions within the Texatron(TM) platform while collecting engineering data on plasma behavior, operating performance and electrical characteristics.

Management has outlined a staged testing roadmap that includes verification of fusion reactions, measurement of plasma temperature and density, evaluation of pulse-generated electrical output and continued progress toward sustained electricity generation. The company has also stated that data generated during testing is expected to be independently documented, with findings potentially available for publication following appropriate review.

Scientific engagement remains another component of the development strategy.

American Fusion(TM) recently announced that Chief Technology Officer Dr. John Brandenburg would present the Texatron(TM) Fusion Engine(TM) platform at a particle physics conference hosted by Fermi National Accelerator Laboratory (Fermilab), providing an opportunity to discuss the technology with researchers working across particle physics, plasma science and related disciplines.

Management has emphasized that independent scientific evaluation will play an important role as the company advances through successive engineering milestones.

Commercial planning is also becoming more defined. During the executive interview, Nelson identified AI and hyperscale data centers among the company’s most immediate target markets, citing rapidly growing electricity demand driven by artificial intelligence infrastructure. Additional markets identified by management include industrial facilities, mining operations, defense installations, strategic infrastructure and longer-term space applications.

The addition of a Chief Revenue Officer reflects the company’s intention to begin developing commercial relationships well before technology deployment reaches later stages of maturity.

Alongside commercialization efforts, American Fusion(TM) continues expanding what management views as another long-term corporate asset: its intellectual property portfolio. On July 23, the company announced the filing of 19 additional U.S. patent applications, bringing its total to 76 filed applications while maintaining a stated objective of eventually filing more than 260 patents covering the Texatron(TM) platform and related technologies (https://ibn.fm/ah5Oz).

The latest filings span reactor architecture, plasma confinement, electromagnetic systems, fuel delivery, reactor control and power management technologies, reflecting the company’s strategy of protecting multiple components of its broader engineering platform rather than individual reactor designs alone. American Fusion(TM) has indicated that protecting those innovations remains a central element of its long-term business model.

At the same time, engineering teams have continued preparing the testing environment at Texas Tech University through installation and calibration of vacuum systems, diagnostic instrumentation, electronics, remote switching equipment and data acquisition systems needed for the next phase of technical evaluation.

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to AMFN are available in the company’s newsroom at https://ibn.fm/AMFN

• Regentis is advancing GelrinC through a pivotal stage of development, with key catalysts including U.S. clinical study enrollment, European commercialization activities, and continued manufacturing optimization.
• Strategic interest in cartilage regeneration technologies was highlighted by Smith+Nephew’s acquisition of CartiHeal for up to $330 million, underscoring the potential value of innovative orthopedic solutions designed to address unmet needs in cartilage repair.
• GelrinC is an off-the-shelf, cell-free, one-step hydrogel-based implant designed to simplify cartilage repair through a procedure that supports and mimics the body’s natural regenerative processes.

Cartilage Regeneration Gains Strategic Validation

The orthopedic industry is increasingly focused on technologies that can address cartilage damage by promoting tissue regeneration rather than simply managing symptoms. This opportunity gained additional validation when Smith+Nephew completed its acquisition of CartiHeal, a developer of cartilage repair technology, in a transaction valued at up to $330 million. The acquisition demonstrated growing strategic interest among major orthopedic companies in regenerative approaches designed to improve joint repair outcomes and expand treatment options for patients suffering from cartilage defects.

This activity provides important context for Regentis as it develops next-generation cartilage repair solutions. As established medical technology companies continue seeking differentiated platforms capable of addressing significant unmet needs in orthopedics, GelrinC’s off-the-shelf, cell-free profile and practical surgical workflow position it within a market segment increasingly recognized for both clinical and strategic commercial value.

Regentis Advances GelrinC Toward Multiple Milestones

Within this evolving market landscape, Regentis Biomaterials (NYSE American: RGNT) is advancing GelrinC, its proprietary hydrogel-based cartilage regeneration platform designed to provide an off-the-shelf, cell-free solution for cartilage repair. Unlike traditional approaches that may require cell harvesting, laboratory expansion, or more complex treatment workflows, GelrinC is designed to be administered through a streamlined single-step surgical procedure while supporting tissue regeneration.

The company is advancing on several important clinical, regulatory, commercial, and manufacturing fronts. Key priorities include continued enrollment in its U.S. clinical study, preparation for a Premarket Approval (“PMA”) submission to the U.S. Food and Drug Administration (“FDA”), ongoing commercialization activities in Europe, and continued manufacturing optimization to support product consistency, scalability, and broader adoption.

Building a Foundation for Commercial Scale

Beyond clinical advancement, Regentis is building the infrastructure required to support commercial adoption. In Europe, where GelrinC has already secured CE Mark approval, the company has moved from development planning into commercial activities, including hands-on surgeon training, Centers of Excellence engagement, market education, and discussions with potential distribution partners.

This commercial readiness addresses many of the practical requirements for adoption in orthopedic markets. Surgeons need familiarity with the implantation procedure, hospitals need products that fit existing operating room workflows, and commercial partners need confidence that the product can be supplied consistently and on a scale.

Regentis’ continued focus on manufacturing optimization and product consistency supports this broader commercialization strategy. For a cell-free, off-the-shelf product such as GelrinC, scalable manufacturing is not only a technical requirement – it is a key commercial advantage compared with more complex cell-based therapies that require patient-specific harvesting, processing, and reimplantation.

A Potentially Transformative Approach to Cartilage Repair

GelrinC represents Regentis’ effort to address limitations associated with existing cartilage repair procedures by providing a biomaterial-based platform designed to support durable cartilage regeneration while simplifying treatment. With CE Mark approval already secured in Europe, commercialization activities underway, and multiple development milestones ahead in the United States, the company has reached an important stage in its transition from clinical development toward broader commercialization.

As strategic acquisitions continue to underscore the value of cartilage regeneration technologies, Regentis’ progress across clinical, regulatory, manufacturing, and commercial initiatives could provide investors with increasing visibility into GelrinC’s long-term commercial potential and the broader opportunity within regenerative orthopedics.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at ibn.fm/RGNT

This content was disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid marketing engagement with IBN.Ai

RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising.

• Drones play a crucial role in modern military operations, but it’s becoming increasingly more important for these drones to operate without relying on GPS, due to the prevalence of jamming and other issues.
• Growing demand for GPS-independent drone navigation has prompted companies such as Robotto to pivot their technologies toward defense applications.
• Another company operating in this expanding market is SPARC AI, which develops GPS-free target acquisition and autonomous navigation software for drones and other edge devices.

Few technologies have reshaped modern warfare as dramatically as unmanned aerial systems (“drones”). They provide real-time battlefield intelligence, logistical support and precision capabilities while keeping personnel farther from danger. Compared with many traditional military platforms, drones also offer a relatively low-cost solution that can be deployed at scale.

However, as electronic warfare becomes more sophisticated, it is no longer enough simply to deploy drones, they must also be capable of operating without GPS.

The reason is simple: electronic warfare has become a defining feature of modern conflict. GPS jamming overwhelms legitimate satellite signals, while GPS spoofing transmits false positioning data intended to mislead navigation systems. Both tactics can severely limit the effectiveness of conventional drones.

Both jamming and spoofing are frequently used in war, so if your drones aren’t capable of operating in compromised zones or signal-contested areas, they may not be nearly as useful as they could be. As a result, drones that rely exclusively on satellite navigation can lose effectiveness in contested environments, increasing demand for alternative navigation and targeting technologies.

Because of the growing importance of GPS-free navigation in war and the demand for drones equipped with these capabilities, some companies are shifting and have shifted to support this growing industry.

One example is Robotto, a Danish startup that originally developed drone software for wildfire detection and forest mapping. Following Russia’s invasion of Ukraine, the company adapted its technology for GPS-independent military targeting after being approached by a former Danish Army colleague. Today, its software has reportedly been deployed on more than 5,000 drones supporting “find, fix, finish” missions in Ukraine.

Another company positioned to benefit from this evolving defense landscape is SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF). The company develops next-generation GPS-free target acquisition and autonomous navigation software for drones and other edge devices.

SPARC AI’s software-only platform uses zero-signature technology to provide real-time detection, tracking and behavioral analysis without relying on radar, lidar or other sensor-heavy hardware. The company’s objective is to combine mathematics, artificial intelligence and edge computing into a unified intelligence platform.

Built on more than 15 years of research and development, SPARC AI’s Target Acquisition System geolocates visible objects using camera telemetry data. By constructing a three-dimensional understanding of terrain and position, the platform is designed to deliver GPS-level accuracy without emitting detectable signals.

Essentially, it constructs a 3D understanding of terrain and position, which can help achieve GPS-level accuracy in a zero-signature configuration. The platform also supports terrain-based navigation using proprietary AI models and XYZ orientation, enabling operation in environments where satellite signals are denied or degraded.

Purpose-built for Denied, Degraded, Intermittent and Limited (“DDIL”) environments, the software requires no additional hardware or costly external sensors, helping reduce both power consumption and operating costs.

As military organizations increasingly prioritize resilient autonomous systems capable of operating in electronically contested environments, GPS-independent navigation is becoming a strategic necessity rather than a niche capability. Companies developing software-first solutions designed for these conditions, including SPARC AI, may be well positioned as governments continue investing in next-generation defense technologies.

For more information, visit the company’s website at https://sparcai.co.

NOTE TO INVESTORS: The latest news and updates relating to SPAIF are available in the company’s newsroom at https://ibn.fm/SPAIF

Disseminated on behalf of Numa Numa Resources Inc. and may include paid advertisements.

• Geographically part of the Solomon Islands archipelago, Bougainville has been politically linked to Papua New Guinea since the colonial era.
• One of the central questions surrounding Bougainville’s independence is economic viability.
• Numa Numa is working with landowner groups and local stakeholders to advance mining opportunities while respecting Bougainville’s legal framework and customary ownership systems.

For Bougainville, the path to independence is about more than politics. It is also about economics. As the autonomous Pacific region continues discussions regarding its future political status, the development of its vast mineral resources has emerged as one of the most important factors in determining whether an independent Bougainville can build a sustainable and prosperous economy. Numa Numa Resources is among the companies seeking to help unlock that potential through partnerships with landowners and infrastructure development tied to some of the region’s most significant mineral assets.

Bougainville occupies a unique place in the Pacific. Although geographically part of the Solomon Islands archipelago, it has been politically linked to Papua New Guinea since the colonial era. Following Papua New Guinea’s independence in 1975, tensions in Bougainville increasingly centered on questions of political representation, economic participation and the management of natural resources. Those tensions were amplified by the presence of the Panguna Mine, one of the world’s largest copper and gold operations during its years of production.

The Panguna Mine began production in 1972 and quickly became an economic powerhouse. At its peak, it generated as much as 45% of Papua New Guinea’s export revenue. While the mine created substantial wealth, many Bougainvilleans felt that local communities received an inadequate share of the economic benefits while bearing the environmental and social impacts associated with mining activities.

These grievances became one of several factors that contributed to the Bougainville conflict, known as “the Crisis,” which lasted from 1988 to 1998 and resulted in the closure of the Panguna Mine. The conflict ultimately led to the Bougainville Peace Agreement in 2001, which established a framework for autonomy and future political consultations regarding Bougainville’s status. The agreement created the autonomous Bougainville government and provided a pathway for a referendum on independence.

That referendum took place in 2019. According to official results reported by the Bougainville Referendum Commission and documented by international observers, 97.7% of voters chose independence over continued autonomy within Papua New Guinea. While the referendum was nonbinding and final implementation remains subject to negotiations between Bougainville and Papua New Guinea, the result demonstrated overwhelming public support for self-government.

One of the central questions surrounding independence is economic viability. Any newly independent nation must generate sufficient revenue to fund government services, infrastructure, healthcare, education and economic development. For Bougainville, mineral resources represent one of the most significant potential sources of future revenue.

The importance of copper in particular has increased in recent years as electrification and renewable energy deployment drive demand for the metal. The International Energy Agency has identified copper as one of the critical minerals essential to energy transition technologies, including electric vehicles, power grids and renewable generation systems. This global demand has renewed interest in major undeveloped copper deposits around the world, including those located in Bougainville.

As discussions about Bougainville’s future continue, many observers view resource development as a key component of any long-term economic strategy. The challenge is ensuring that future projects are developed differently than they were in the past. Lessons from the Panguna experience have highlighted the importance of local participation, transparent governance, environmental stewardship and meaningful benefit-sharing arrangements with customary landowners.

This is where Numa Numa Resources has positioned itself. Numa Numa is working with landowner groups and local stakeholders to advance mining opportunities while respecting Bougainville’s legal framework and customary ownership systems. The company’s strategy emphasizes collaboration with resource owners and community engagement as part of the development process.

Numa Numa is also investing in infrastructure designed to support long-term economic development. The company reports that it is constructing the first east-west road across Bougainville’s mountainous central mining district since before the civil conflict. Such infrastructure can provide benefits that extend beyond resource extraction by improving transportation access, facilitating commerce and connecting isolated communities.

In addition, Numa Numa has entered into agreements with landowners associated with areas surrounding the Panguna resource district. The company has stated that these agreements support development efforts connected to an estimated $100 billion copper and gold resource opportunity within the region. While the ultimate value of any mineral deposit depends on numerous technical and economic factors, the scale of the resource illustrates why mining remains central to conversations about Bougainville’s future.

For Bougainville, independence and economic development are closely linked. The region possesses significant natural resources, a population that has expressed strong support for self-government and a growing focus on rebuilding infrastructure and institutions. Whether independence ultimately becomes a reality will depend on political negotiations, but many believe that responsible resource development will play a critical role in shaping the region’s long-term prospects.

Numa Numa Resources is operating at the intersection of those ambitions. By working with landowners, supporting infrastructure projects and pursuing opportunities tied to Bougainville’s mineral wealth, the company is participating in a broader effort to help create the economic foundation that many supporters view as essential to Bougainville’s future.

For more information, visit www.NumaNumaResources.com.

NOTE TO INVESTORS: The latest news and updates relating to Numa Numa are available in the company’s newsroom at https://ibn.fm/NUMA